Viridian Therapeutics, Inc. Common Stock (VRDN) Stock Price

VRDNStock
$24.18+24.94%52W
Market Cap$2.74B
P/E
PEG Ratio
Div yield
Beta1.09

VRDN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-25.80%
Price vs S&P 500 (4W)20.06%
VGM Score63.38

VRDN Earnings Surprise History

Q2 25-1.00est. -0.98
Q3 25-0.34est. -0.94
Q4 25-1.08est. -1.00
Q1 26-0.90est. -1.08
Q2 26-1.05est. -1.03

VRDN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.21
4.26
4.30
4.30

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
VRDNViridian Therapeutics, Inc. Common Stock
DAB$24.18
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Viridian Therapeutics, Inc. Common Stock

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease. Its lead candidate, Veligrotug, is a humanized monoclonal antibody targeting IGF-1R, available in both intravenous and subcutaneous formulations.